Guidant gains FDA nod for ENDOTAK ICD (implantable cardioverter defibrillator) lead:
This article was originally published in Clinica
Executive Summary
Guidant has gained FDA go-ahead to market in the US its ENDOTAK reliance active-fixation defibrillation lead, which it says features a simplified fixation system that allows smooth deployment into the heart wall. The lead, which transmits signals between the heart and the ICD device, has fluoroscopic markers to enable surgeons to clearly see the helix-shaped tip extending into the tissue. The product will be released in the US later this month, said the firm.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.